Rice University announced a new climate tech initiative backed by Woodside Energy. Photo by Natalie Harms/InnovationMap

Rice University has announced its latest initiative to advance clean energy technology into commercialization with a new partnership with a global energy company.

Woodside Energy, headquartered in Australia with its global operations in Houston following its 2022 acquisition of BHP Group, has committed $12.5 million over the next five years to create the Woodside Rice Decarbonization Accelerator.

"The goal of the accelerator is to fast track the commercialization of innovative decarbonization technologies created in Rice labs," Rice University President Reginald DesRoches says to a crowd at the Ion at the initiative's announcement. "These technologies have the potential to make better batteries, transitistors, and other critical materials for energy technologies. In addition, the accelerator will work on manufacturing these high-value products from captured and converted carbon dioxide and methane."

"The Woodside Rice Decarbonization Accelerator will build on the work that Rice has been doing in advanced materials, energy, energy transition, and climate for many years. More than 20 percent of our faculty do some related work to energy and climate," he continues. "Harnessing their efforts alongside an esteemed partner like Woodside Energy is an exciting step that will undoubtedly have an impact far and wide."

Woodside, which has over 800 employees based in Houston, has been a partner at the Ion since last spring. Daniel Kalms, Woodside Energy's CTO and executive vice president, explains that the new initiative falls in line with the three goals of Woodside's climate strategy, which includes keeping up with global energy demand, creating value, and conducting its business sustainably. The company has committed a total of $5 billion to new energy by 2030, Kalms says.

"We know that the world needs energy that is more affordable, sustainable, and secure to support the energy transition — and we want to provide that energy. Energy that is affordable, sustainable, and secure requires innovation and the application of new technology. That's what this is about," he says.

"Of course collaboration will be the key," Kalms continues. "By working with researchers, entrepreneurs, leading experts and parallel industries, we can combine our capability to solve collective challenges and create shared opportunities. That's why we are excited to be partnering with Rice."

The accelerator will be run by Paul Cherukuri, vice president of innovation at Rice University, and Aditya Mohite, associate professor of Chemical and Biomolecular Engineering and Materials Science and Nanoengineering. Additional Rice professors will be involved as well, Cherukuri says.

"Success for us will not be papers, it will be products," Cherukuri says of what Woodside wants from the partnership. "We picked faculty at Rice in particular who were interested in taking on this charge, and they were all faculty who created companies."

Last fall, Rice announced a grant and venture initiative to accelerate innovation from Rice in the biotech space.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.